Pioglitazone Compared to Glibenclamide on Lipid Profile and Inflammation Markers in Type 2 Diabetic Patients During an Oral Fat Load

Abstract

The aim of the study was to evaluate the effect of pioglitazone and glibenclamide on lipid profile and inflammatory parameters during an oral fat load (OFL). A total of 201 type 2 diabetic patients on treatment with metformin were enrolled in the study; pioglitazone was titrated till 45 mg/day and glibenclamide till 15 mg/day, in association with metformin, respectively. The patients underwent an OFL at baseline and after 12 months. The OFL was given between 08.00 and 09.00 h after a 12-h fast. Blood samples were drawn before and 3, 6, 9, and 12 h after the OFL. We evaluated glycemic-metabolic parameters [glycated hemoglobin (HbA_1c), fasting plasma glucose (FPG), fasting plasma insulin (FPI), homeostasis model assessment (Homa) index], total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tgs), interleukin-6 (IL-6), high sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), and adiponectin (ADN). Pioglitazone was better than glibenclamide in decreasing HbA_1c, FPG, FPI, lipid profile, and in improving inflammatory parameters such as Hs-CRP, and ADN. Comparing the OFL performed at baseline, and the OFL performed at the end of the study, pioglitazone, but not glibenclamide, improved all post-OFL peaks for all parameters. Comparing the 12 months OFL in the group treated with pioglitazone and in the group treated with glibenclamide, the values recorded with pioglitazone were significantly better than the ones obtained with glibenclamide. We can conclude that pioglitazone was better than glibenclamide in mitigating the variations of lipid components and inflammation parameters in type 2 diabetic patients.

Key words

pioglitazone - glibenclamide - type 2 diabetes mellitus - oral fat load - inflammation

References

• 1 Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.  Biochem Biophys Res Commun. 1996;  224 431-437
• 2 Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.  Diabetes. 1998;  47 507-514
• 3 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma.  J Biol Chem. 1995;  270 12953-12956
• 4 Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes.  Diabetes. 1996;  45 1661-1669
• 5 Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ. BRL 49653C normalizes glycemic control in Zucker fatty fa/fa rats by improving hepatic and peripheral tissue sensitivity to insulin.  Diabetologia. 1993;  36 A184
• 6 European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Accessible at: http://www.ema.europa.eu
• 7 Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PROactive investigators . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.  Lancet. 2005;  366 (9493) 1279-1289
• 8 Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.  Drugs. 2010;  70 1945-1961
• 9 Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.  Diabetes Obes Metab. 2009;  11 1091-1099
• 10 Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.  JAMA. 2007;  298 299-308
• 11 Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis.  Atherosclerosis. 1994;  106 83-97
• 12 Parks EJ. Recent findings in the study of postprandial lipemia.  Curr Atheroscler Rep. 2001;  3 462-470
• 13 Halkes CJ, van Dijk H, de Jaegere PP, Plokker HW, van Der Helm Y, Erkelens DW, Castro Cabezas M. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin.  Arterioscler Thromb Vasc Biol. 2001;  21 1526-1530
• 14 Alipour A, Elte JW, van Zaanen HC, Rietveld AP, Cabezas MC. Postprandial inflammation and endothelial dysfunction.  Biochem Soc Trans. 2007;  35 466-469
• 15 Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, Eriksson P, Catapano AL. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies.  Atherosclerosis. 2007;  193 321-327
• 16 Tsai WC, Li YH, Lin CC, Chao TH, Chen JH. Effects of oxidative stress on endothelial function after a high-fat meal.  Clin Sci. 2004;  106 315-319
• 17 Jastrzebska M, Przybycień K, Chelstowski K, Torbus-Lisiecka B, Kornacewicz-Jach Z, Naruszewicz M. Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography.  Nutr Metab Cardiovasc Dis. 1999;  9 33-40
• 18 Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia.  Arterioscler Thromb. 1994;  14 60-69
• 19 Derosa G, Ferrari I, D’Angelo A, Salvadeo SAT, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AFG. Oral fat load effects on inflammation and endothelial stress markers in healthy subjects.  Heart Vessels. 2009;  24 204-210
• 20 Derosa G, Ferrari I, D’Angelo A, Salvadeo SAT, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AFG. Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects.  Microvasc Res. 2010;  80 110-115
• 21 Derosa G, Maffioli P, Ferrari I, Fogari E, D’Angelo A, Palumbo I, Randazzo S, Bianchi L, Cicero AFG. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load.  Eur J Pharmacol. 2011;  651 240-250
• 22 Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Gravina A, Mereu R, Palumbo I, D’Angelo A, Cicero AFG. Candesartan effect on inflammation in hypertension.  Hypertens Res. 2010;  33 209-213
• 23 Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus.  Drugs. 2004;  64 1339-1358
• 24 Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes.  Diabetes Technol Ther. 2010;  12 491-501
• 25 Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD) . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).  Eur Heart J. 2007;  28 88-136
• 26 Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture.  CMAJ. 2007;  177 723-724
• 27 Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006.  Arterioscler Thromb Vasc Biol. 2006;  26 2186-2191
• 28 Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Gravina A, Mereu R, D’Angelo A, Palumbo I, Randazzo S, Cicero AFG. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.  Metabolism. 2011;  60 421-429
• 29 Winer BJ. Statistical Principles in Experimental Design.. 2nd ed New York: McGraw-Hill; 1971
• 30 Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Ragonesi PD, Querci F, Pranzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D’Angelo A, Cicero AFG. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.  Metabolism. 2010;  59 887-895
• 31 Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D’Angelo A, Salvadeo SAT. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.  Horm Metab Res. 2010;  42 663-669
• 32 Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Gravina A, Mereu R, Palumbo I, D’Angelo A, Cicero AFG. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.  Metabolism. 2009;  58 1059-1066
• 33 Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G. ADOPT Study Group . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.  N Engl J Med. 2006;  355 2427-2443
• 34 Haufe S, Engeli S, Budziarek P, Utz W, Schulz-Menger J, Hermsdorf M, Wiesner S, Otto C, Fuhrmann JC, Luft FC, Boschmann M, Jordan J. Determinants of exercise-induced fat oxidation in obese women and men.  Horm Metab Res. 2010;  42 215-221
• 35 Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease.  Nat Clin Pract Cardiovasc Med. 2006;  3 35-42
• 36 David CW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis.  Am J Physiol Heart Circ Physiol. 2005;  288 H2031-H2041
• 37 Tritos NA, Mantzoros CS. Leptin: its role in obesity and beyond.  Diabetologica. 1997;  40 1371-1379
• 38 Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages.  Circulation. 2001;  103 1194-1197
• 39 McBride PE. Triglycerides and risk for coronary heart disease.  JAMA. 2007;  298 336-338
• 40 Maggi FM, Raselli S, Grigore L, Redaelli L, Fantappiè S, Catalano AL. Lipoprotein remnants and endothelial dysfunction in the postprandial phase.  J Clin Endocrinol Metab. 2004;  89 2946-2950

Correspondence